Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency

Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency (also known as CYP7A1 deficiency) is a rare inherited lipid metabolism disorder caused by mutations in the CYP7A1 gene, which encodes the enzyme cholesterol 7alpha-hydroxylase. This enzyme catalyzes the rate-limiting step in the classical bile acid synthesis pathway, converting cholesterol into bile acids in the liver. When this enzyme is deficient, cholesterol cannot be adequately converted to bile acids, leading to accumulation of cholesterol in the blood and liver. The condition primarily affects the hepatic and cardiovascular systems. Patients typically present with markedly elevated total cholesterol and LDL cholesterol levels, often resistant to standard statin therapy (HMG-CoA reductase inhibitors). This is because statins work partly by upregulating LDL receptors through a mechanism that involves bile acid synthesis, and when CYP7A1 is deficient, this feedback pathway is disrupted. Affected individuals may also have reduced bile acid pools, hypertriglyceridemia, and premature gallstone formation. The hypercholesterolemia places patients at increased risk for premature atherosclerosis and cardiovascular disease. Treatment is challenging because of the relative resistance to conventional lipid-lowering therapies. Bile acid sequestrants may have limited efficacy due to the underlying defect in bile acid synthesis. Some patients may respond to combination lipid-lowering therapy, and newer agents targeting alternative pathways of cholesterol metabolism may offer benefit. Dietary modifications and lifestyle interventions are also recommended as part of comprehensive management. Given the rarity of this condition, management is typically guided by lipid specialists with experience in monogenic dyslipidemias.

Common questions about Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency